基于索非布韦的丙型肝炎治疗方案在中国单中心的十年回顾性队列研究

IF 2 Q3 INFECTIOUS DISEASES
Qiao Yang, Fangping Xu, Yi Shen, Borui Pi, Fangfang Lv
{"title":"基于索非布韦的丙型肝炎治疗方案在中国单中心的十年回顾性队列研究","authors":"Qiao Yang, Fangping Xu, Yi Shen, Borui Pi, Fangfang Lv","doi":"10.1097/im9.0000000000000131","DOIUrl":null,"url":null,"abstract":"Abstract This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral regimens in the heterogeneous population of patients with chronic hepatitis C (CHC) in clinical practice. This retrospective cohort study included CHC patients attending the Sir Run Run Shaw Hospital between January 1, 2012 and December 31, 2022. All of the 194 patients treated with SOF-based regimens completed 12 weeks of treatment and were followed up for at least 12 weeks after completion of the therapy. Sustained virologic response (SVR) 12 weeks after the end of treatment was the primary endpoint. A total of 194 patients treated with SOF-based regimens were included, among which 121, 56, 10 and 7 patients received SOF + velpatasvir±ribavirin, SOF + daclatasvir, SOF + ledipasvir or SOF + ribavirin, respectively. With 36.1%, HCV genotype 1 predominated in CHC patients treated with SOF-based regimens, followed by genotype 2a with 17.5% and genotype 3 with 14.9%. Comorbidities among patients included hypertension (4.1%), diabetes (2.1%), depression (1.0%) and neoplastic disease (2.6%). All patients treated with SOF-based regimens achieved SVR. There was no association between SVR and factors such as HCV genotype, sex, age, presence of cirrhosis or previous treatment history. There were no reports of any serious adverse events in the study. This single-center retrospective study represented the latest 10-year treatment trends for HCV in real-world clinical practice and provided useful information on the excellent efficacy of SOF-based direct-acting antiviral regimens for treatment of CHC patients in Eastern China.","PeriodicalId":73374,"journal":{"name":"Infectious microbes & diseases","volume":"60 7-8","pages":"0"},"PeriodicalIF":2.0000,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China\",\"authors\":\"Qiao Yang, Fangping Xu, Yi Shen, Borui Pi, Fangfang Lv\",\"doi\":\"10.1097/im9.0000000000000131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral regimens in the heterogeneous population of patients with chronic hepatitis C (CHC) in clinical practice. This retrospective cohort study included CHC patients attending the Sir Run Run Shaw Hospital between January 1, 2012 and December 31, 2022. All of the 194 patients treated with SOF-based regimens completed 12 weeks of treatment and were followed up for at least 12 weeks after completion of the therapy. Sustained virologic response (SVR) 12 weeks after the end of treatment was the primary endpoint. A total of 194 patients treated with SOF-based regimens were included, among which 121, 56, 10 and 7 patients received SOF + velpatasvir±ribavirin, SOF + daclatasvir, SOF + ledipasvir or SOF + ribavirin, respectively. With 36.1%, HCV genotype 1 predominated in CHC patients treated with SOF-based regimens, followed by genotype 2a with 17.5% and genotype 3 with 14.9%. Comorbidities among patients included hypertension (4.1%), diabetes (2.1%), depression (1.0%) and neoplastic disease (2.6%). All patients treated with SOF-based regimens achieved SVR. There was no association between SVR and factors such as HCV genotype, sex, age, presence of cirrhosis or previous treatment history. There were no reports of any serious adverse events in the study. This single-center retrospective study represented the latest 10-year treatment trends for HCV in real-world clinical practice and provided useful information on the excellent efficacy of SOF-based direct-acting antiviral regimens for treatment of CHC patients in Eastern China.\",\"PeriodicalId\":73374,\"journal\":{\"name\":\"Infectious microbes & diseases\",\"volume\":\"60 7-8\",\"pages\":\"0\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious microbes & diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/im9.0000000000000131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious microbes & diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/im9.0000000000000131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

摘要本研究旨在回顾近十年来丙型肝炎病毒(HCV)的治疗趋势,并分析基于索非布韦(SOF)的直接抗病毒治疗方案在异质慢性丙型肝炎(CHC)患者中的临床应用效果。本回顾性队列研究纳入2012年1月1日至2022年12月31日在邵逸夫爵士医院就诊的CHC患者。所有194名接受基于soff方案治疗的患者完成了12周的治疗,并在治疗完成后随访至少12周。治疗结束后12周的持续病毒学应答(SVR)是主要终点。共纳入194例以软膏为基础的方案,其中软膏+维帕他韦±利巴韦林121例,软膏+ daclatasvir 56例,软膏+ ledipasvir 10例,软膏+利巴韦林7例。在以sofd为基础的方案治疗的CHC患者中,HCV基因1型占36.1%,其次是基因2a型占17.5%,基因3型占14.9%。患者合并症包括高血压(4.1%)、糖尿病(2.1%)、抑郁症(1.0%)和肿瘤疾病(2.6%)。所有接受基于sofs方案治疗的患者均达到SVR。SVR与HCV基因型、性别、年龄、是否存在肝硬化或既往治疗史等因素无相关性。研究中没有任何严重不良事件的报告。这项单中心回顾性研究代表了现实世界临床实践中HCV治疗的最新10年趋势,并为基于sofd的直接作用抗病毒方案治疗中国东部CHC患者的卓越疗效提供了有用的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China
Abstract This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past decade and to analyze the effectiveness of sofosbuvir (SOF)-based direct-acting antiviral regimens in the heterogeneous population of patients with chronic hepatitis C (CHC) in clinical practice. This retrospective cohort study included CHC patients attending the Sir Run Run Shaw Hospital between January 1, 2012 and December 31, 2022. All of the 194 patients treated with SOF-based regimens completed 12 weeks of treatment and were followed up for at least 12 weeks after completion of the therapy. Sustained virologic response (SVR) 12 weeks after the end of treatment was the primary endpoint. A total of 194 patients treated with SOF-based regimens were included, among which 121, 56, 10 and 7 patients received SOF + velpatasvir±ribavirin, SOF + daclatasvir, SOF + ledipasvir or SOF + ribavirin, respectively. With 36.1%, HCV genotype 1 predominated in CHC patients treated with SOF-based regimens, followed by genotype 2a with 17.5% and genotype 3 with 14.9%. Comorbidities among patients included hypertension (4.1%), diabetes (2.1%), depression (1.0%) and neoplastic disease (2.6%). All patients treated with SOF-based regimens achieved SVR. There was no association between SVR and factors such as HCV genotype, sex, age, presence of cirrhosis or previous treatment history. There were no reports of any serious adverse events in the study. This single-center retrospective study represented the latest 10-year treatment trends for HCV in real-world clinical practice and provided useful information on the excellent efficacy of SOF-based direct-acting antiviral regimens for treatment of CHC patients in Eastern China.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信